In the Bergen Psychosis Project 2 the antipsychotic drugs aripiprazole, amisulpride, and
olanzapine will be compared head-to-head in patients with schizophrenia and related psychoses
and followed for 12 months. The study is independent of the pharmaceutical industry, and in
accordance with a pragmatic design a clinically relevant sample will be included with as few
exclusion criteria as possible. The patients will be assessed repeatedly with regards to
symptoms, side effects, and cognitive functioning, as well as laboratory parameters. The
study hypothesis is that clinically meaningful differences among the drugs will be disclosed
in a pragmatic design.